Literature DB >> 2703164

Determinants of increased risk for recurrence in patients undergoing radical hysterectomy for stage IB and IIA carcinoma of the cervix.

A F Fuller1, N Elliott, C Kosloff, W J Hoskins, J L Lewis.   

Abstract

From 1939 to 1977, 431 patients underwent radical hysterectomy as primary therapy for Stage IB or IIA carcinoma of the cervix at Memorial Sloan-Kettering Cancer Center. Only 11 patients were lost to follow-up at intervals of from 1 to 94 months. Assessment of gross and histologic extent of disease was correlated with the prevalence of nodal metastases and survival. Increasing tumor size, depth of invasion, and histologic grade were covariable and predictive of both lymph node metastases and recurrence. After stratifying for nodal metastases, adenocarcinoma cell type, the size of the primary tumor, depth of invasion into the cervix, and histologic grade were associated with decreased survival. For the 85 patients with documented recurrence of their carcinoma, the time to recurrence varied inversely with primary tumor size. Of 56 patients with documented recurrence and negative nodes at the time of their initial therapy, 10 patients (18%) were ultimately salvaged. None of the 29 patients with recurrent carcinoma and positive nodes at the time of their initial lymphadenectomy was successfully treated. Analysis of prognostic factors identifies a group of patients at high risk for recurrence and decreased survival for whom prospective trials of adjunctive treatment should be considered.

Entities:  

Mesh:

Year:  1989        PMID: 2703164     DOI: 10.1016/0090-8258(89)90598-2

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  33 in total

1.  Clinical efficacy of nedaplatin-based concurrent chemoradiotherapy for uterine cervical cancer: a Tohoku Gynecologic Cancer Unit Study.

Authors:  Masahiro Kagabu; Tadahiro Shoji; Kazuyuki Murakami; Hideo Omi; Tatsuya Honda; Fumiharu Miura; Yoshihito Yokoyama; Hideki Tokunaga; Tadao Takano; Tsuyoshi Ohta; Dai Shimizu; Naoki Sato; Shu Soeda; Takafumi Watanabe; Hidekazu Yamada; Hideki Mizunuma; Nobuo Yaegashi; Satoru Nagase; Toru Tase; Toru Sugiyama
Journal:  Int J Clin Oncol       Date:  2016-01-19       Impact factor: 3.402

Review 2.  Sentinel lymph node evaluation in women with cervical cancer.

Authors:  Laura L Holman; Charles F Levenback; Michael Frumovitz
Journal:  J Minim Invasive Gynecol       Date:  2014-01-07       Impact factor: 4.137

3.  Sensitivity and negative predictive value for sentinel lymph node biopsy in women with early-stage cervical cancer.

Authors:  Gloria Salvo; Pedro T Ramirez; Charles F Levenback; Mark F Munsell; Elizabeth D Euscher; Pamela T Soliman; Michael Frumovitz
Journal:  Gynecol Oncol       Date:  2017-02-08       Impact factor: 5.482

4.  Comparison of 18F-FDG PET/MRI and MRI for pre-therapeutic tumor staging of patients with primary cancer of the uterine cervix.

Authors:  Theresia Sarabhai; Benedikt M Schaarschmidt; Axel Wetter; Julian Kirchner; Bahriye Aktas; Michael Forsting; Verena Ruhlmann; Ken Herrmann; Lale Umutlu; Johannes Grueneisen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08-24       Impact factor: 9.236

5.  Adjuvant radiochemotherapy in patients with locally advanced high-risk cervical cancer.

Authors:  F Heinzelmann; G Henke; M von Grafenstein; N Weidner; F Paulsen; A Staebler; S Brucker; M Bamberg; M Weinmann
Journal:  Strahlenther Onkol       Date:  2012-05-23       Impact factor: 3.621

6.  Long-term outcomes of postoperative taxane/platinum chemotherapy for early stage cervical cancer: a retrospective study.

Authors:  Mika Okazawa-Sakai; Takanori Yokoyama; Etsuko Fujimoto; Shinichi Okame; Yuko Shiroyama; Takashi Yokoyama; Kazuhiro Takehara
Journal:  Int J Clin Oncol       Date:  2018-02-14       Impact factor: 3.402

7.  Sentinel lymph node detection rates using indocyanine green in women with early-stage cervical cancer.

Authors:  Anna L Beavis; Sergio Salazar-Marioni; Abdulrahman K Sinno; Rebecca L Stone; Amanda N Fader; Antonio Santillan-Gomez; Edward J Tanner
Journal:  Gynecol Oncol       Date:  2016-08-12       Impact factor: 5.482

8.  HPV and histological status of pelvic lymph node metastases in cervical cancer: a prospective study.

Authors:  K Lukaszuk; J Liss; I Wozniak; W Sliwinski; J Emerich; C Wojcikowski
Journal:  J Clin Pathol       Date:  2004-05       Impact factor: 3.411

9.  Neoadjuvant chemotherapy with cisplatin, vincristine, and bleomycin and radical surgery in early-stage bulky cervical carcinoma.

Authors:  H C Chang; C H Lai; P C Chou; C J Tseng; T C Chang; S Hsueh; Y S Ho; Y K Soong
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

10.  Fluorescence in situ hybridization markers for prediction of cervical lymph node metastases.

Authors:  Darawalee Wangsa; Kerstin Heselmeyer-Haddad; Patricia Ried; Elina Eriksson; Alejandro A Schäffer; Larry E Morrison; Juhua Luo; Gert Auer; Eva Munck-Wikland; Thomas Ried; Elisabeth Avall Lundqvist
Journal:  Am J Pathol       Date:  2009-11-05       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.